Success Stories: EB-1A Petition Approved in 13 Days for Senior Scientist in New Jersey in the Field of Pharmacology
Client’s Testimonial:
“Thanks for the information and support.”
On March 8th, 2017, we received another EB-1A (Alien of Extraordinary Ability) approval for a Senior Scientist in the Field of Pharmacology (Approval Notice).
General Field: Pharmacology
Position at the Time of Case Filing: Senior Scientist
Country of Origin: India
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filing: New Jersey
Approval Notice Date: March 8th, 2017
Processing Time: 13 Days (Premium Processing Requested)
Case Summary:
Just 13 days after North America Immigration Law Group (NAILG) filed an EB-1A (Alien of Extraordinary Ability) petition on behalf of a senior scientist from India, the USCIS approved his case. With extensive experience carrying out studies in the field of pharmacology, our client has met 3 out of the 10 EB1A criteria set by the USCIS. These are the criteria:
- Authorship of scholarly articles in the field, in professional journals, or other major media: We noted the 30 peer-reviewed scientific articles and 3 book chapters in our client’s name and demonstrated that this publication record is exemplary compared to that of his peers.
- Participation on a panel or individually, as a judge of the work of others in the same or a related field: By the time we were ready to file our client’s case, he had already conducted 60 peer reviews. We persuaded the USCIS that this frequent review activity showcased our client’s important standing in the field.
- Original contributions of major significance: We used our client’s citation count as proof that he has significantly contributed to the field of pharmacology. Thanks to Google Scholar, we confirmed that our client’s work had amassed 179 citations at the time of filing.
As we were able to demonstrate the importance of our client’s work on drug delivery and formulation—important issues in understanding efficient methods for producing pharmaceutical drugs in the United States—the USCIS granted him EB1A petition approval. We congratulate him on this win and thank him for retaining us to help him and his dependent with their I-485 applications.

